Search Results
-
Post
Novocure Reports Second Quarter 2020 Financial Results and Provides Company Update
...or Optune Lua that is received from a physician certified to treat patients for a patient not previously on Optune or Optune Lua. Orders to renew or extend treatment are...
-
Post
Novocure and Zai Lab Announce Strategic Collaboration with a License Agreement for Tumor Treating Fields in Greater China
Zai Lab granted license to commercialize oncology platform technology Tumor Treating Fields, including the brand name Optune®, in China, Hong Kong, Macau and Taiwan Zai Lab will support enrollment of...
-
Post
Novocure Enrolls Last Patient in PANOVA Trial of Tumor Treating Fields Plus Chemotherapy in Advanced Pancreatic Cancer
...For additional information about the company, please visit www.novocure.com or follow us at www.twitter.com/novocure. Approved Indications In the United States, Optune is intended as a treatment for adult patients (22...
-
Post
Novocure Enrolls Last Patient in INNOVATE Trial Testing Tumor Treating Fields Plus Paclitaxel in Recurrent Ovarian Cancer
...Israel. For additional information about the company, please visit www.novocure.com or follow us at www.twitter.com/novocure. Approved Indications In the United States, Optune is intended as a treatment for adult patients...
-
Post
Novocure Announces Presentation of Subgroup Analysis of PANOVA Data Showing Overall Survival Benefit of Tumor Treating Fields Plus Gemcitabine in Advanced Pancreatic Cancer Patients
...United States, Optune is intended as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM). In the United States, Optune with temozolomide is...
-
Post
Novocure to Present New Preclinical Data on Tumor Treating Fields at American Association for Cancer Research Annual Meeting 2016
...In the United States, Optune is intended as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM). In the United States, Optune with...
-
Post
Novocure and Leading Cancer Center Enter a Preclinical Research Collaboration to Study Tumor Treating Fields
...normal mitotic process and causing cancer cell death. Approved Indications In the United States, Optune is intended as a treatment for adult patients (22 years of age or older) with...
-
Post
Preliminary Phase 2 Data Demonstrate Tumor Treating Fields is Safe in Patients with Brain Metastases Originating from Non-Small Cell Lung Cancer
...States, Optune is intended as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM). In the United States, Optune with temozolomide is indicated...
-
Post
Novocure Announces Presentations on Tumor Treating Fields Therapy, Including New Clinical Data and Real-World Evidence, at 2023 Society for Neuro-Oncology Annual Meeting
...the debut of Novocure’s new Optune Gio™ brand. Optune®, Novocure’s FDA-approved treatment for newly diagnosed and recurrent GBM, will be renamed Optune Gio™ on Nov. 15. Presentations include: Final efficacy...
-
Post
Novocure Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Company Update
...less than 60 days. (3) A “prescription received” is a commercial order for Optune or Optune Lua that is received from a physician certified to treat patients for a patient...